GNKG168

DRUG2 trials

Sponsors

SBI Biotech Co., Ltd., Therapeutic Advances in Childhood Leukemia Consortium

Conditions

LeukemiaRelapsed Acute Lymphoblastic LeukemiaRelapsed Acute Myelogenous Leukemia

Phase 1

A Phase I Study of GNKG168 in Patient With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)

TerminatedNCT01035216

SBI Biotech Co., Ltd.Leukemia

Start: 2009-09-30End: 2013-11-30Updated: 2014-12-23

Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia

TerminatedNCT01743807

Therapeutic Advances in Childhood Leukemia ConsortiumRelapsed Acute Lymphoblastic Leukemia, Relapsed Acute Myelogenous Leukemia

Start: 2014-03-26End: 2014-07-28Updated: 2025-01-27